Gilead Sciences (GILD) Common Equity (2009 - 2026)
Gilead Sciences' (GILD) quarterly Common Equity came in at $23.4 billion in Q1 2026, up 22.82% YoY from $19.1 billion in Q1 2025, and up 3.59% on a QoQ basis from $22.6 billion in Q4 2025.
Gilead Sciences (GILD) Common Equity (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Common Equity data on file, last reported at $23.4 billion in Q1 2026.
- Quarterly Common Equity rose 22.82% year-over-year to $23.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.4 billion (up 22.82% YoY) and the FY2025 annual result came in at $22.6 billion, up 17.52% from the prior year.
- Common Equity grew to $23.4 billion in Q1 2026, from $22.6 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $23.4 billion in Q1 2026 to a low of $17.5 billion in Q1 2024.
- A 5-year average of $20.5 billion and a median of $20.9 billion in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity fell 17.32% — and 2026, when it grew 22.82%.
- Tracing GILD's Common Equity over 5 years: stood at $21.2 billion in 2022, then advanced by 7.26% to $22.7 billion in 2023, then fell by 15.4% to $19.2 billion in 2024, then advanced by 17.52% to $22.6 billion in 2025, then gained by 3.59% to $23.4 billion in 2026.
- The last three Common Equity figures came in at $23.4 billion (Q1 2026), $22.6 billion (Q4 2025), and $21.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.83 Bn |
| Mar 31, 2026 | 23.43 Bn |
| Dec 31, 2025 | 22.62 Bn |
| Sep 30, 2025 | 21.54 Bn |
| Jun 30, 2025 | 19.59 Bn |
| Mar 31, 2025 | 19.08 Bn |
| Dec 31, 2024 | 19.25 Bn |
| Sep 30, 2024 | 18.39 Bn |
| Jun 30, 2024 | 18.20 Bn |
| Mar 31, 2024 | 17.46 Bn |
| Dec 31, 2023 | 22.75 Bn |
| Sep 30, 2023 | 22.24 Bn |
| Jun 30, 2023 | 21.09 Bn |
| Mar 31, 2023 | 20.94 Bn |
| Dec 31, 2022 | 21.21 Bn |
| Sep 30, 2022 | 21.06 Bn |
| Jun 30, 2022 | 20.22 Bn |
| Mar 31, 2022 | 19.92 Bn |
| Dec 31, 2021 | 21.06 Bn |
| Sep 30, 2021 | 21.47 Bn |